Items per page
Sort by

Send to:

Choose Destination

Results: 16

References for PMC Articles for PubMed (Select 21689422)


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators.

Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.


EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.

Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F.

J Clin Pathol. 2009 Nov;62(11):970-7. doi: 10.1136/jcp.2009.066548.


[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].

Cao WG, Ma T, Li JF, Li H, Ji YB, Chen XH, Liu BY, Jin YN.

Ai Zheng. 2007 Dec;26(12):1330-5. Chinese.


Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.


Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

Reuter CW, Morgan MA, Eckardt A.

Br J Cancer. 2007 Feb 12;96(3):408-16. Epub 2007 Jan 16. Review.


Integration of EGFR inhibitors with radiochemotherapy.

Nyati MK, Morgan MA, Feng FY, Lawrence TS.

Nat Rev Cancer. 2006 Nov;6(11):876-85. Epub 2006 Oct 12. Review. Erratum in: Nat Rev Cancer. 2006 Dec;6(12):974.


The complexity of targeting EGFR signalling in cancer: from expression to turnover.

Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A.

Biochim Biophys Acta. 2006 Aug;1766(1):120-39. Epub 2006 Jun 23. Review.


2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.

Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP.

Cancer. 2005 Dec 15;104(12):2701-8.


Identification of novel nuclear localization signal within the ErbB-2 protein.

Chen QQ, Chen XY, Jiang YY, Liu J.

Cell Res. 2005 Jul;15(7):504-10.


[Assessment of HER2 status in breast cancer].

Penault-Llorca F, Cayre A.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Review. French.


Predictive markers in breast and other cancers: a review.

Duffy MJ.

Clin Chem. 2005 Mar;51(3):494-503. Epub 2005 Jan 6. Review.


HER1/EGFR targeting: refining the strategy.

Pérez-Soler R.

Oncologist. 2004;9(1):58-67. Review.


Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.

Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43.


Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Hölscher AH, Danenberg PV.

Clin Cancer Res. 2001 Jul;7(7):1850-5.


Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y.

EMBO J. 1998 Jun 15;17(12):3385-97.


Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.

Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, Kuroki T, Kano K.

J Natl Cancer Inst. 1986 Nov;77(5):1047-52.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk